Brief: Viking Therapeutics Q3 EPS USD -0.81 Vs. IBES Estimate USD -0.7
22/10/2025 21:06
Oct 22 (Reuters) - Viking Therapeutics Q3 operating expenses USD 98.561 million. Q3 income from operations USD -98.561 million vs. IBES estimate USD -85.8 million Q3 net income USD -90.787 million vs. IBES estimate USD -80.8 million
Recent news on Viking Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry